Earlier this month The “New” Prostate Cancer InfoLink stated that the new liquid biopsy test being touted by Pathways Genomics was of no proven value in the diagnosis of prostate cancer and that we expected the U.S. Food and Drug Administration (FDA) would have some comments on the promotion of this test. We were correct.
According to a report on the BloombergBusiness news service, the FDA has told Pathway Genomics that this test is of high risk to healthy individuals, “could harm public health, and hasn’t been validated by science.” To see the FDA’s letter to Pathway Genomics’ CEO, please click here.
Filed under: Diagnosis | Tagged: biopsy, CancerIntercept, genomics, liquid, pathway |
THE "NEW" PROSTATE CANCER INFOLINK 
Leave a Reply